U.S. Markets open in 8 hrs 23 mins
  • S&P Futures

    3,983.25
    +13.00 (+0.33%)
     
  • Dow Futures

    33,935.00
    +64.00 (+0.19%)
     
  • Nasdaq Futures

    11,673.75
    +57.50 (+0.49%)
     
  • Russell 2000 Futures

    1,842.40
    +9.60 (+0.52%)
     
  • Crude Oil

    78.55
    +1.31 (+1.70%)
     
  • Gold

    1,753.00
    +12.70 (+0.73%)
     
  • Silver

    21.27
    +0.35 (+1.70%)
     
  • EUR/USD

    1.0389
    +0.0044 (+0.4259%)
     
  • 10-Yr Bond

    3.7030
    0.0000 (0.00%)
     
  • Vix

    22.21
    +1.71 (+8.34%)
     
  • GBP/USD

    1.2009
    +0.0044 (+0.3639%)
     
  • USD/JPY

    138.5740
    -0.3270 (-0.2354%)
     
  • BTC-USD

    16,482.88
    +309.70 (+1.91%)
     
  • CMC Crypto 200

    388.91
    +8.62 (+2.27%)
     
  • FTSE 100

    7,474.02
    -12.65 (-0.17%)
     
  • Nikkei 225

    28,027.82
    -135.01 (-0.48%)
     

Is Ocugen a Buy?

Is Ocugen a Buy?

Despite several face-melting crashes, Ocugen's (NASDAQ: OCGN) stock rose more than 666% this year so far, and it might have further to go, provided that its flagship coronavirus vaccine gets cleared for sales in North America. What will regulators do? The biggest questions facing Ocugen at the moment are which regulators will greenlight its vaccine, and whether any of those potential green lights might actually translate into significant revenue.